AbbVie Inc. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. AbbVie Inc. operates as a single global business segment focused on immunology, neuroscience, oncology, and aesthetics. The company reported strong revenue growth driven by new product launches and market share gains, offset by significant non-cash charges related to contingent consideration and business development.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $15,002 million | $13,343 million |
| Operating Earnings | $3,990 million | $3,733 million |
| Net Earnings (Attributable to AbbVie) | $695 million | $1,286 million |
| Diluted EPS | $0.39 | $0.72 |
| Operating Cash Flow | $3,829 million | $1,635 million |
| Cash and Equivalents (End of Period) | $9,391 million | $5,175 million |
| Total Debt (Current + Long-term) | $72,858 million | $65,000 million (approx.) |
| Effective Tax Rate | 33% | 22% |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 12.4% (10.3% at constant currency) year-over-year. Growth was driven by Skyrizi (+29.2% constant currency), Rinvoq (+20.2%), and Qulipta (+51.3%). This was partially offset by a 40.3% decline in Humira revenues due to biosimilar competition.
- Profitability Impact: While operating earnings increased, net earnings declined 46% primarily due to a $2.4 billion charge for the change in fair value of contingent consideration liabilities (up from $1.5 billion in Q1 2025) and a $650 million upfront charge for the RemeGen license agreement.
- Debt Structure: The company issued $8.0 billion in new senior notes in March 2026 and repaid a $2.0 billion short-term term loan, resulting in a net increase in total debt.
- Cash Position: Cash and equivalents more than doubled to $9.4 billion, driven by strong operating cash flows and new debt issuance.
Outlook, Risks, and Management Commentary
- Pipeline Progress: AbbVie submitted an FDA application for Skyrizi for Crohn's disease and Rinvoq for vitiligo and alopecia areata. The company received a Complete Response Letter (CRL) for TrenibotE regarding manufacturing processes, with no safety or efficacy concerns noted.
- Strategic Investments: Management announced a $100 billion pledge in U.S. R&D and capital investments over the next decade under a voluntary agreement with the U.S. government, securing a three-year exemption from tariffs and price mandates.
- Shareholder Returns: The quarterly dividend was increased to $1.73 per share. The company repurchased 5 million shares for $1.1 billion, with approximately $1.8 billion remaining in repurchase authorization.
- Legal Contingencies: Significant litigation remains regarding Niaspan antitrust claims, opioid liability (Allergan), and breast implant (ALCL) claims. A tax dispute regarding a 2014 transaction was resolved in AbbVie's favor in February 2026.
- Regulatory Risks: Botox was selected for government-set pricing in Medicare Parts B and D beginning in 2028 under the Inflation Reduction Act.
Investor Verification Checklist
- Contingent Consideration Volatility: Verify the sensitivity of the $27 billion contingent consideration liability to changes in Skyrizi sales forecasts and discount rates, as this significantly impacts net earnings.
- Humira Decline Trajectory: Monitor the rate of Humira revenue erosion against the growth of Skyrizi and Rinvoq to assess the sustainability of the revenue transition.
- Debt Service Capacity: Review the impact of the new $8 billion debt issuance on future interest expense and liquidity, given the current high-interest environment.
- Regulatory Pricing Impact: Assess the potential financial impact of the 2028 Medicare price mandates on Botox and other key products.
- Legal Accruals: Track the $1.7 billion litigation accrual balance for potential increases related to opioid and breast implant proceedings.